Century Club · Limited Partner Invitation · 2026

Get on Track
to 100.

The longevity economy is forming. We are assembling a founding group of partners to shape its infrastructure, standards, and scale.

Healthy aging - vibrant senior person embodying longevity
Scroll to explore
Our Thesis

Our thesis is based on the belief that people can live and thrive to 100.

We bring more vital years of life to our LPs through our Century Club, and then to the world by funding longevity innovation.

01
Fund the full spectrum of longevity innovation — clinical breakthroughs, nutritional science, and beyond.
02
Accelerate the adoption of longevity science from lab to everyday life.
03
Democratize longevity science at a global scale — making healthy aging a universal right.
The Opportunity

Longevity is a multi-hundred-billion-dollar healthcare investment opportunity.

$314B+
Projected market size by 2030
$8B+
Deployed in longevity in 2024 alone
~25%
Annual category growth rate (CAGR)
1 in 6
People globally over age 60 by 2030
A Complete Longevity Ecosystem

The Four Investment Pillars

1 — Discovery

Therapies & Modalities

Evidence-based longevity drugs, peptides, and biologics. Metabolic modulators, senolytics, mitochondrial therapeutics.

2 — Clinical

Care Infrastructure & Physician Networks

Provider networks, IPAs, MSOs, telehealth longevity groups. Modular clinical models for longevity clinicians.

3 — Distribution

Access, Distribution & Data

Distribution logistics, access automation, adherence systems. End-to-end routing platforms and data analytics.

4 — Consumer

Consumer Longevity Ecosystems

Credible nutraceuticals, cosmeceuticals, functional wellness. Adherence and lifestyle integration tools.

Leadership

The Architect of Modern Longevity

Dr. Robert Goldman
Founder & Chairman, BioSpan Longevity Fund

Dr. Robert M. Goldman is one of the world's most recognized pioneers in the science and global movement of longevity. Co-founder and longtime chairman of A4M, he has shaped the modern longevity industry for over 30 years.

Co-Founder, A4M
Physician / PhD Biochemistry
$940M Exit — Tarsus Medical
150+ Patents, $100M+ R&D
Fund Architecture

Institutional structure.
Venture precision.

Fund Structure

Built for focus, not dispersion.
$300–500M Total Fund
12–18 Core Portfolio Companies
2–3 New Investments Per Year
Series A/B Only

Ownership Discipline

Control secured before consensus.
15–25% Initial Equity at Entry
Pro-Rata Rights Maintained
20–30% Follow-On Reserves
Board-Level Governance

Return Architecture

Value engineered before repricing.
$25M–$75M Entry (Series A/B)
3–5x Inflection Before Next Round
3.0–3.5x Target MOIC
25–30% Target IRR
BIOSPANLONGEVITYVENTURES

We invite you
to join us.

Together, we can invest in the double bottom line of multiples, and multiplied time.

Aligned capital · Long-duration conviction · Shared upside
info@biospanfund.com